Tips for Summer Safety
Many people love the warm sun, beaches, and gardens, but along with those beautiful summer days comes the threat of sun damage. What does this mean for GIST patients?
Many people love the warm sun, beaches, and gardens, but along with those beautiful summer days comes the threat of sun damage. What does this mean for GIST patients?
The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]
A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]
The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
The European Commission recently announced that Stivarga (regorafenib) from Bayer has been approved in the European Union (EU) as a third line treatment for GIST.
Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]
Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information.Official Stivarga Press Release:Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing of Regorafenib (Stivarga) [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.